Cargando…

Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients

BACKGROUND: Because of previous ventricular arrhythmia (VA) episodes, patients with implantable cardioverter-defibrillator (ICD) for secondary prevention (SP) are generally considered to have a higher burden of VAs than primary prevention (PP) patients. However, when PP patients experienced VA, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, You, Zhao, Shuang, Chen, Keping, Hua, Wei, Su, Yangang, Chen, Silin, Liang, Zhaoguang, Xu, Wei, Zhang, Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805511/
https://www.ncbi.nlm.nih.gov/pubmed/31638918
http://dx.doi.org/10.1186/s12872-019-1218-9
_version_ 1783461402543915008
author Zhou, You
Zhao, Shuang
Chen, Keping
Hua, Wei
Su, Yangang
Chen, Silin
Liang, Zhaoguang
Xu, Wei
Zhang, Shu
author_facet Zhou, You
Zhao, Shuang
Chen, Keping
Hua, Wei
Su, Yangang
Chen, Silin
Liang, Zhaoguang
Xu, Wei
Zhang, Shu
author_sort Zhou, You
collection PubMed
description BACKGROUND: Because of previous ventricular arrhythmia (VA) episodes, patients with implantable cardioverter-defibrillator (ICD) for secondary prevention (SP) are generally considered to have a higher burden of VAs than primary prevention (PP) patients. However, when PP patients experienced VA, the difference in the prognosis of these two patient groups was unknown. METHODS: The clinical characteristics and follow-up data of 835 ICD patients (364 SP patients and 471 PP patients) with home monitoring feature were retrospectively analysed. The incidence rate and risk of subsequent VA and all-cause mortality were compared between PP patients after the first appropriate ICD therapy and SP patients. RESULTS: During a mean follow-up of 44.72 ± 20.87 months, 210 (44.59%) PP patients underwent appropriate ICD therapy. In the Kaplan-Meier survival analysis, the PP patients after appropriate ICD therapy were more prone to VA recurrence and all-cause mortality than SP patients (P<0.001 for both endpoints). The rate of appropriate ICD therapy and all-cause mortality in PP patients after the first appropriate ICD therapy was significantly higher than that in SP patients (for device therapy, 59.46 vs 20.64 patients per 100 patient-years; incidence rate ratio [IRR] 2.880, 95% confidence interval [CI]: 2.305–3.599; P<0.001; for all-cause mortality, 14.08 vs 5.40 deaths per 100 patient-years; IRR 2.607, 95% CI: 1.884–3.606; P<0.001). After propensity score matching for baseline characteristics, the risk of VA recurrence in PP patients with appropriate ICD therapy was still higher than that in SP patients (41.80 vs 19.10 patients per 100 patient-years; IRR 2.491, 95% CI: 1.889–3.287; P<0.001), but all-cause mortality rates were similar between the two groups (12.61 vs 9.33 deaths per 100 patient-years; IRR 1.352, 95% CI: 0.927–1.972; P = 0.117). CONCLUSIONS: Once PP patients undergo appropriate ICD therapy, they will be more prone to VA recurrence and death than SP patients.
format Online
Article
Text
id pubmed-6805511
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68055112019-10-24 Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients Zhou, You Zhao, Shuang Chen, Keping Hua, Wei Su, Yangang Chen, Silin Liang, Zhaoguang Xu, Wei Zhang, Shu BMC Cardiovasc Disord Research Article BACKGROUND: Because of previous ventricular arrhythmia (VA) episodes, patients with implantable cardioverter-defibrillator (ICD) for secondary prevention (SP) are generally considered to have a higher burden of VAs than primary prevention (PP) patients. However, when PP patients experienced VA, the difference in the prognosis of these two patient groups was unknown. METHODS: The clinical characteristics and follow-up data of 835 ICD patients (364 SP patients and 471 PP patients) with home monitoring feature were retrospectively analysed. The incidence rate and risk of subsequent VA and all-cause mortality were compared between PP patients after the first appropriate ICD therapy and SP patients. RESULTS: During a mean follow-up of 44.72 ± 20.87 months, 210 (44.59%) PP patients underwent appropriate ICD therapy. In the Kaplan-Meier survival analysis, the PP patients after appropriate ICD therapy were more prone to VA recurrence and all-cause mortality than SP patients (P<0.001 for both endpoints). The rate of appropriate ICD therapy and all-cause mortality in PP patients after the first appropriate ICD therapy was significantly higher than that in SP patients (for device therapy, 59.46 vs 20.64 patients per 100 patient-years; incidence rate ratio [IRR] 2.880, 95% confidence interval [CI]: 2.305–3.599; P<0.001; for all-cause mortality, 14.08 vs 5.40 deaths per 100 patient-years; IRR 2.607, 95% CI: 1.884–3.606; P<0.001). After propensity score matching for baseline characteristics, the risk of VA recurrence in PP patients with appropriate ICD therapy was still higher than that in SP patients (41.80 vs 19.10 patients per 100 patient-years; IRR 2.491, 95% CI: 1.889–3.287; P<0.001), but all-cause mortality rates were similar between the two groups (12.61 vs 9.33 deaths per 100 patient-years; IRR 1.352, 95% CI: 0.927–1.972; P = 0.117). CONCLUSIONS: Once PP patients undergo appropriate ICD therapy, they will be more prone to VA recurrence and death than SP patients. BioMed Central 2019-10-21 /pmc/articles/PMC6805511/ /pubmed/31638918 http://dx.doi.org/10.1186/s12872-019-1218-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Zhou, You
Zhao, Shuang
Chen, Keping
Hua, Wei
Su, Yangang
Chen, Silin
Liang, Zhaoguang
Xu, Wei
Zhang, Shu
Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients
title Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients
title_full Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients
title_fullStr Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients
title_full_unstemmed Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients
title_short Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients
title_sort risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805511/
https://www.ncbi.nlm.nih.gov/pubmed/31638918
http://dx.doi.org/10.1186/s12872-019-1218-9
work_keys_str_mv AT zhouyou riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients
AT zhaoshuang riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients
AT chenkeping riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients
AT huawei riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients
AT suyangang riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients
AT chensilin riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients
AT liangzhaoguang riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients
AT xuwei riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients
AT zhangshu riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients